Author:
Al Kaabi Nawal,Oulhaj Abderrahim,Al Hosani Farida Ismail,Al Mazrouei Shamma,Najim Omer,Hussein Salah Eldin,Abdalla Jehad Saleh,Fasihuddin Mohammed Saifuddin,Hassan Afnan Abdellatif,Elghazali Gehad,Al Rumaithi Ahmed,Al Azazi Jumana,Weber Stefan,Beiram Rami,Parekh Khatija A.,Sheek-Hussein Mohamud,Yang Yunkai,Xiaoming Yang,Quliang Jenny,Eltantawy Islam,Mahmoud Sally,Koshy Ashish,Xiao Peng,Ganesan Subhashini,Elamin Wael,Zaher Walid
Abstract
AbstractBased on the findings from the Phase III clinical trials of inactivated SARS COV-2 Vaccine, (BBIBP-CORV) emergency use authorization (EUA) was granted for the vaccine to frontline workers in the UAE. A prospective cohort study was conducted among frontline workers to estimate the incidence rate and risk of symptomatic COVID-19 infection 14 days after the second dose of inoculation with BBIBP-CORV inactivated vaccine. Those who received two doses of the BBIBP-CORV vaccine in the period from 14th of September 2020 (first dose) to 21st of December 2020 (second dose) were followed up for COVID-19 infections. 11,322 individuals who received the two-dose BBIBP-CORV vaccine were included and were followed up post the second dose plus fourteen days. The incidence rate of symptomatic infection was 0.08 per 1000-person days (95% CI 0.07, 0.10). The estimated absolute risk of developing symptomatic infection was 0.97% (95% CI 0.77%, 1.17%). The confirmed seroconversion rate was 92.8%. There were no serious adverse events reported and no individuals suffered from severe disease. Our findings show that vaccinated individuals are likely to remain protected against symptomatic infection or becoming PCR positive for SARS COV 2 following the second dose of the vaccination.
Publisher
Springer Science and Business Media LLC
Reference26 articles.
1. WHO Coronavirus Disease (COVID-19) Dashboard | WHO Coronavirus Disease (COVID-19) Dashboard. https://covid19.who.int/. Accessed 15 Nov 2021.
2. World Health Organization (WHO). News. WHO lists additional COVID-19 vaccine for emergency use and issues interim policy recommendations. https://www.who.int/news/item/07-05-2021-who-lists-additional-covid-19-vaccine-for-emergency-use-and-issues-interim-policy-recommendations. Accessed 8 March 2021.
3. Xia, S. et al. Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: interim analysis of 2 randomized clinical trials. JAMA J. Am. Med. Assoc. 324, 951–960 (2020).
4. Wang, H. et al. Development of an inactivated vaccine candidate, BBIBP-CorV, with potent protection against SARS-CoV-2. Cell 182, 713-721.e9 (2020).
5. Xia, S. et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial. Lancet Infect. Dis. 21, 39–51 (2021).
Cited by
10 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献